The first Elsevier issue of NeuroRx will appear in January 2006. Alan I. Faden, M.D., Professor of Neuroscience at Georgetown University Medical Center, will continue to serve as Editor-in-Chief. "Partnering with Elsevier will help us continue to expand the reach of NeuroRx, supporting our mission of bridging the gap between basic neuroscience research and the development of effective new treatments for neurological diseases," comments Dr. Faden.

NeuroRx is a unique publication providing critical reviews on selected topics in therapy of neurological disorders. Each quarterly issue focuses on a single topic, with internationally recognized authorities sharing their in-depth understanding. NeuroRx offers a multidisciplinary perspective on high-profile topics in neurotherapeutics, taking in not just the scientific issues but also their social and ethical ramifications.

The information provided by NeuroRx is equally valuable to neuroscientists performing basic research and clinicians working in neurology, neurosurgery, psychiatry, and rehabilitation medicine. Scheduled topics for the 2006 issues of NeuroRx are Neuropsychiatry; Pediatric Neurotherapeutics; Neurorehabilitation and Neurorestoration; and Proteomics, Genomics, Metabolomics. Dr. Faden adds, "These are among the critical topics at the frontiers of translational neuroscience, with the potential to lead to new treatments for important diseases of the brain and nervous system."

Members of ASENT will continue to receive the print edition of NeuroRx. Members and subscribers will be able to access the entire contents of each issue online at the journal website, www.neurorx.org. Other online feature
'"/>

Contact: Janet Massey
j.massey@elsevier.com
215-239-3652
Elsevier
5-Jan-2006